ESPR Stock Overview
A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Esperion Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.65 |
| 52 Week High | US$3.40 |
| 52 Week Low | US$0.70 |
| Beta | 1 |
| 11 Month Change | -18.72% |
| 3 Month Change | -41.07% |
| 1 Year Change | 18.71% |
| 33 Year Change | -86.03% |
| 5 Year Change | -95.49% |
| Change since IPO | -88.62% |
Recent News & Updates
Esperion Therapeutics: Strategically Positioned To Grow
Aug 16Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
May 20Recent updates
Esperion Therapeutics: Strategically Positioned To Grow
Aug 16Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
May 20A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Feb 28Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Jan 22Esperion Is Sitting On A Potential Blockbuster Drug
Jan 14Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Jun 19
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
Mar 09Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%
Feb 23Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol
Aug 26Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Aug 09Esperion Therapeutics Q2 2022 Earnings Preview
Aug 01Esperion Therapeutics: 2021 Labors Paying Off In 2022
May 07Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout
Feb 24Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022
Jan 20Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection
Oct 27Esperion: Hunting Big Game In The Danger Zone
Aug 05Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year
May 09Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 04Shareholder Returns
| ESPR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.8% | -3.1% | -4.4% |
| 1Y | 18.7% | 16.1% | 19.1% |
Return vs Industry: ESPR exceeded the US Pharmaceuticals industry which returned 17.4% over the past year.
Return vs Market: ESPR underperformed the US Market which returned 21.3% over the past year.
Price Volatility
| ESPR volatility | |
|---|---|
| ESPR Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ESPR's share price has been volatile over the past 3 months.
Volatility Over Time: ESPR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 240 | Sheldon Koenig | www.esperion.com |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
Esperion Therapeutics, Inc. Fundamentals Summary
| ESPR fundamental statistics | |
|---|---|
| Market cap | US$323.77m |
| Earnings (TTM) | -US$98.50m |
| Revenue (TTM) | US$277.79m |
1.2x
P/S Ratio-3.3x
P/E RatioIs ESPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESPR income statement (TTM) | |
|---|---|
| Revenue | US$277.79m |
| Cost of Revenue | US$108.00m |
| Gross Profit | US$169.78m |
| Other Expenses | US$268.28m |
| Earnings | -US$98.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 61.12% |
| Net Profit Margin | -35.46% |
| Debt/Equity Ratio | -76.3% |
How did ESPR perform over the long term?
See historical performance and comparison